Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
Giorgio Valabrega, Matthew A Powell, Sakari Hietanen, Eirwen M Miller, Zoltan Novak, Robert Holloway, Dominik Denschlag, Tashanna Myers, Anna M Thijs, Kathryn P Pennington, Lucy Gilbert, Evelyn Fleming, Oleksandr Zub, Lisa M Landrum, Beyhan Ataseven, Radhika Gogoi, Iwona Podzielinski, Noelle Cloven, Bradley J Monk, Sudarshan Sharma, Thomas J Herzog, Ashley Stuckey, Bhavana Pothuri, Angeles Alvarez Secord, Dana Chase, Veena Vincent, Oren Meyers, Jamie Garside, Mansoor Raza Mirza, Destin Black
International Journal of Gynecologic Cancer Sep 2024, ijgc-2024-005484; DOI: 10.1136/ijgc-2024-005484
